June 10, 2015
Below are current clinical trials.24 studies in Obesity
(open studies only).
Filter this list of studies by location, status and more.
A variety of liver insults lead to pathological changes in liver architecture that culminate in cirrhosis. While invasive liver biopsy was required to detect cirrhosis, the development of magnetic resonance elastography (MRE) has revolutionized our ability to detect liver fibrosis through non-invasive means that involve measurement of liver stiffness. However, a number of pathological findings occur in liver in response to various insults that precede cirrhosis and are clinically important to identify such as steatosis associated with NASH, inflammation associated with viral hepatitis, and congestion associated with cardiac hepatopathy. Detection of such entities provides essential diagnostic, prognostic, and treatment information but yet is not available non-invasively. Recent murine studies from this group of investigators has identified that MRE technology can be adapted to non-invasively detect these conditions. Implementing this into the practice will transform it by obviating the need for invasive liver biopsies in patients suspected of having such forms of suspected liver disease. This will differentiate Mayo from other institutions where such technology is not available.
An additional aim of this study is to examine the impact of obstructive sleep apnea (OSA) on the pathogenesis of nonalcoholic fatty liver disease (NAFLD), both common comorbidities of obesity. Recent evidence indicates a potential link between OSA and severity of NASH and fibrosis, but the mechanisms of OSA- associated hypoxia on liver disease progression in NAFLD is unclear. This study offers the unique opportunity to analyze this association, as the study population will undergo routine evaluation for OSA, as part as the preoperative work-up prior to bariatric surgery.
The purpose of this study is to assess changes that occur in the intestine microbe environment of obese people as they perticipate in a structured diet and lifestyle modification.
The purpose of this study is to see why the ability of fat cells to respond to insulin is different depending on body shape and how fat tissue inflammation is involved.
This study is being done to better understand the relationship between inflammation and insulin resistance in your Adipose (fat) Tissue .
A prospective, multicenter, open-label, post-approval study of the safety and effectiveness of ORBERA™ as an adjunct to weight reduction for obese adults (22 years of age and older) with a Body Mass Index (BMI) of ≥ 30 kg/m2 and BMI ≤ 40 kg/m2
Investigators are doing this research study to find out the effect of T6 dermatomal electrical stimulation (delivered by a Transcutaneous Electrical Nerve Stimulation (TENS) unit) on appetite and weight loss.
This research study is being done to evaluate the reliability and reproducibility of an infrared 3D scanner and an iPad app in measuring body measurements in participants.
The main objective of this study is to establish a national pediatric obesity registry known as POWER (Pediatric Obesity Weight Evaluation Registry). This registry will contain clinical data from individual comprehensive pediatric weight management programs around the United States for overweight and obese youth.
The overall goal of this study is the prospective evaluation of children with severe combined immunodeficiency and related disorders who are treated under a variety of protocols at multiple participating institutions. The study aims to identify variables contributing to the best outcomes for stem cell transplant as treatment for severe combined immunodeficiency disorder.
Observational studies suggest that bariatric surgery is the most effective intervention for weight loss. Comparative effectiveness of Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG) demonstrate that RYGB is significantly superior to SG in terms of weight loss and glycemic control. Both RYGB and SG increase GLP-1 concentrations which directly affect B-cell function. Data has shown that the postprandial rise in GLP-1 might affect feeding behavior after RYGB and to a lesser extent SG, where the increase in GLP-1 is less marked. In this study the investigators propose to randomize subjects undergoing SG to receive either placebo or Liraglutide, a GLP-1 receptor agonist, to compare weight loss and CV risk factors.
- AskMayoExpert. Obesity. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014.
- Defining overweight and obesity. Centers for Disease Control and Prevention. http://www.cdc.gov/obesity/adult/defining.html. Accessed March 9, 2015.
- Jensen MD, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Journal of the American College of Cardiology. 2014;63(25 Pt B):2985.
- Bray GA. Pathogenesis of obesity. http://www.uptodate.com/home. Accessed March 9, 2015.
- What are overweight and obesity? National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/obe#. Accessed March 9, 2015.
- Bray GA. Obesity in adults: Etiology and natural history. http://www.uptodate.com/home. Accessed March 9, 2015.
- Bray GA. Obesity in adults: Health hazards. http://www.uptodate.com/home. Accessed March 9, 2015.
- Understanding adult overweight and obesity. National Institute of Diabetes and Digestive and Kidney Diseases. http://win.niddk.nih.gov/publications/understanding.htm. Accessed March 9, 2015.
- Papadakis MA, et al. Nutritional disorders. In: Current Medical Diagnosis & Treatment 2014. 53rd ed. New York, N.Y.: The McGraw-Hill Companies; 2014. http://www.accessmedicine.com. Accessed March 9, 2015
- Sacks F, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. New England Journal of Medicine. 2009;360:859.
- Moyer VA, et al. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine. 2012;157:373.
- Bray GA. Obesity in adults: Drug therapy. http://www.uptodate.com/home. Accessed March 9, 2015.
- Greenberger NJ, et al. Treatment of obesity: The impact of bariatric surgery. In: Current Diagnosis & Treatment: Gastroenterology, Hepatology, & Endoscopy. 2nd ed. New York, N.Y.: The McGraw-Hill Companies; 2012. http://www.accessmedicine.com. Accessed March 9, 2015.
- Nelson DW, et al. Analysis of obesity-related outcomes and bariatric failure rates with the duodenal switch vs. gastric bypass for morbid obesity. Archives of Surgery. 2012;147:847.
- Weight control and complementary health practices: What the science says. National Center for Complementary and Integrative Health. http://nccih.nih.gov/health/providers/digest/weightloss-science. Accessed March 9, 2015.
- FDA approves first of kind device to treat obesity. U.S. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm430223.htm. Accessed Jan. 27, 2015.
- Pharmacological management of obesity: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2015;100:342.
- Kim SB. Surgical management of severe obesity. http://www.uptodate.com/home. Accessed March 12, 2015.
- Ikramuddin S, et al. Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: The ReCharge randomized clinical trial. JAMA. 2014;312:915.
- Hensrud DD, et al., eds. The Mayo Clinic Diet. Intercourse, Pa.: Good Books; 2013.